BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 13, 2025
See today's BioWorld MedTech
See today's BioWorld
Home
» Advisory committee meetings becoming a rarity at the FDA?
To read the full story,
subscribe
or
sign in
.
Advisory committee meetings becoming a rarity at the FDA?
Sep. 16, 2025
By
Mari Serebrov
No Comments
Recent comments from CDER Director George Tidmarsh suggesting that the agency may be backing away from the use of its independent expert panels for individual product approvals seem to be supported by the numbers.
BioWorld
BioWorld MedTech
Analysis and data insight
Regulatory
U.S.
FDA
Policy